NCT05491642View on ClinicalTrials.gov

A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 8, 2022

Primary Completion Date

January 3, 2023

Study Completion Date

April 28, 2023

Conditions
Chronic Kidney DiseaseHypertension
Interventions
DRUG

BAY3283142

Oral administration

DRUG

Placebo to BAY3283142

Oral administration

Trial Locations (4)

1612

Medical Center Comac Medical EOOD, Sofia

10117

Charité Research Organisation GmbH, Berlin

20251

CTC North GmbH & Co. KG, Hamburg

68167

CRS Clinical-Research-Services Mannheim GmbH, Mannheim

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses | Biotech Hunter | Biotech Hunter